Incyte (INCY) Deferred Taxes (2021 - 2026)
Incyte's (INCY) quarterly Deferred Taxes came in at $115.6 million in Q2 2026, down 0.99% YoY from $116.8 million in Q2 2025, and up 82.32% on a QoQ basis from $63.4 million in Q1 2026.
Incyte (INCY) Deferred Taxes (2021 - 2026) Analysis & Trends
Incyte (INCY) has 6 years of Deferred Taxes data on file, last reported at $115.6 million in Q2 2026.
- Quarterly Deferred Taxes fell 0.99% year-over-year to $115.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$178.7 million (down 224.2% YoY) and the FY2025 annual result came in at -$247.7 million, down 389.51% from the prior year.
- Deferred Taxes advanced to $115.6 million in Q2 2026, from $63.4 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $116.8 million in Q2 2025 to a low of -$344.3 million in Q3 2025.
- A 5-year average of $6.6 million and a median of $19.8 million in 2023 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2022 — Deferred Taxes slumped 44305.56% — and 2023, when it jumped 1152.37%.
- Tracing INCY's Deferred Taxes over 5 years: stood at -$16.7 million in 2022, then soared by 496.06% to $66.0 million in 2023, then sank by 100.08% to -$56000.0 in 2024, then tumbled by 24001.79% to -$13.5 million in 2025, then soared by 956.64% to $115.6 million in 2026.
- The last three Deferred Taxes figures came in at $115.6 million (Q2 2026), $63.4 million (Q1 2026), and -$13.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 115.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.62 Mn |
| Mar 31, 2026 | 63.42 Mn |
| Dec 31, 2025 | -13.50 Mn |
| Sep 30, 2025 | -344.26 Mn |
| Jun 30, 2025 | 116.78 Mn |
| Mar 31, 2025 | -6.71 Mn |
| Dec 31, 2024 | -56,000.00 |
| Sep 30, 2024 | 33.88 Mn |
| Jun 30, 2024 | 17.48 Mn |
| Mar 31, 2024 | 34.25 Mn |
| Dec 31, 2023 | 65.98 Mn |
| Sep 30, 2023 | 31.06 Mn |
| Jun 30, 2023 | 39.70 Mn |
| Mar 31, 2023 | 22.16 Mn |
| Dec 31, 2022 | -16.66 Mn |
| Sep 30, 2022 | -7.96 Mn |
| Jun 30, 2022 | -30.37 Mn |
| Mar 31, 2022 | -2.11 Mn |
| Dec 31, 2021 | 465.43 Mn |
| Sep 30, 2021 | 18,000.00 |